Safety and immunogenicity of an investigational respiratory syncytial virus vaccine (RSVPreF3) in mothers and their infants: a phase 2 randomized trial.

Zourab BebiaOsvaldo ReyesRobert JeanfreauAnu KanteleRuth Graciela De LeonMarta García SánchezPeyman BanooniGlenn J GardenerJosé Luis Bartha RaseroMaria Begoña Encinas PardillaJoanne M LangleyClaudio Maañón Di LeoElisabeth Botelho-NeversJim ButteryHelene LaurichesseShabir A MadhiAdrián Martín GarcíaThorsten StanleyTiphaine BarjatRebecca GriffithMaria Mercedes Castrejón-AlbaMagali de HeuschIlse DieussaertMelanie HercorPatricia LeseHui QianAntonella N TullioOuzama Henry

Published in: The Journal of infectious diseases (2023)

RSVPreF3 maternal vaccination had an acceptable safety risk profile and induced robust RSV-specific immune responses with successful antibody transfer to their newborns.

Keyphrases

respiratory syncytial virus
immune response
pregnant women
high glucose
diabetic rats
toll like receptor
oxidative stress
clinical trial
physical activity
endothelial cells
pregnancy outcomes
preterm infants
weight loss
body mass index
inflammatory response
cord blood
phase iii